Article
Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.
Hematological oncology - 1 Oct 2020
Flach Johanna, Shumilov Evgenii, Wiedemann Gertrud, Porret Naomi, Shakhanova Inna, Bürki Susanne, Legros Myriam, Joncourt Raphael, Pabst Thomas, Bacher Ulrike
Abstract excerpt
Relapse of acute myeloid leukemia (AML) remains a major determinant of outcome. A number of molecularly directed treatment options have recently emerged making comprehensive diagnostics an important pillar of clinical decision making at relapse. Acknowledging the high degree of individual genetic variability at AML relapse, next-generation sequencing (NGS) has opened the opportunity for assessing the unique...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.